Un estudio de Orelabrutinib en pacientes con esclerosis múltiple secundaria progresiva
Un estudio de fase 3, aleatorizado, doble ciego, de eficacia y seguridad que compara Orelabrutinib con placebo en pacientes con esclerosis múltiple secundaria progresiva no activa
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with non-active Secondary Progress MS. Patients will be treated for approximately 24 to 60 months, with a minimum treatment duration of 12 months. The study will enroll approximately 990 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with naSPMS. The study will enroll approximately 990 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.
The study consists of the following periods:
- Screening Period: Up to 4 weeks.
- Treatment Period: The duration of treatment will vary for individual participants ranging from approximately 24 to 60 months, depending on the time of recruitment. A month is defined as a period of 28 days by convention.
- Double-blinded (DB) Treatment: All eligible participants will be randomized at 2:1 ratio to accept orelabrutinib QD or placebo during the DB treatment period. The study will be unblinded when all participants in the DB period have reached a minimum treatment duration of 12 months at the time of primary analysis timing cutoff.
- Open-label (OL) Treatment: Participants with 24-week CDP as assessed by EDSS are eligible for 2-year open-label orelabrutinib treatment.
- Safety Follow-Up Period: It will last 4 weeks. The safety follow-up period will begin when the participants discontinue from the treatment before the end of the trial for any reasons or complete the trial but do not enter the long-term safety study (LTS) (see below).
All active study participants will have a final end of study (EOS) visit within 4 weeks of the study end date. Participants who are receiving IMP in DB or OL but do not consent to or are not eligible for enrollment in the LTS study, must return for a final safety follow-up visit 4 weeks later. For participants who intend and are eligible to join the LTS, open-label treatment with orelabrutinib will continue and no safety follow-up will occur.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Patient and Medical Information
- Número de teléfono: 833-269-4696
- Correo electrónico: clinicaltrialsinfo@zenasbio.com
Copia de seguridad de contactos de estudio
- Nombre: Patient and Medical Information
- Número de teléfono: 833-269-4696
- Correo electrónico: clinialtrialsinfo@zenasbio.com
Ubicaciones de estudio
-
-
Hesse
-
Bad Homburg, Hesse, Alemania, 61348
- Reclutamiento
- Zentrum fur klinische Forschung Dr.Scholl GmbH
-
-
-
-
New South Wales
-
Kogarah, New South Wales, Australia, 2217
- Reclutamiento
- Southern Neurology Suite 2
-
-
-
-
-
Pleven, Bulgaria, 5800
- Reclutamiento
- Avis Medica Hospital Pleven
-
-
Plovdiv
-
Plovdiv, Plovdiv, Bulgaria, 4000
- Reclutamiento
- Medical Center Nevrocentrum
-
-
Sofia
-
Sofia, Sofia, Bulgaria, 1680
- Reclutamiento
- Diagnostic and Consultative Center Convex
-
Sofia, Sofia, Bulgaria, 1510
- Reclutamiento
- Medical Center Hera EOOD
-
-
Tarnovo
-
Veliko Tarnovo, Tarnovo, Bulgaria, 5000
- Reclutamiento
- Medical Center Medica Plus OOD
-
-
-
-
-
Sovet, Bélgica, 1408
- Reclutamiento
- DCC Neoclinic - Sofia
-
-
Limburg
-
Overpelt, Limburg, Bélgica, 3900
- Reclutamiento
- MS-Netwerk Limburg - Revalidatie
-
-
-
-
-
Choceň, Chequia, 56501
- Reclutamiento
- NEUROHK, s.r.o.
-
Jihlava, Chequia, 58601
- Reclutamiento
- Regional Hospital Jihlava
-
-
-
-
-
Zagreb, Croacia, 10 000
- Reclutamiento
- Klinicki Bolnicki Centar Zagreb-Rebro
-
-
-
-
A Coruña
-
A Coruña, A Coruña, España, 15006
- Reclutamiento
- Complejo Hospitalario Universitario A Coruña
-
-
Galicia
-
Vigo, Galicia, España, 36312
- Reclutamiento
- Hospital Alvaro Cunqueiro
-
-
Madrid
-
Madrid, Madrid, España, 28007
- Reclutamiento
- Hospital Gregorio Marañon
-
Majadahonda, Madrid, España, 28222
- Reclutamiento
- Hospital Universitario Puerta de Hierro de Majadahonda
-
-
Málaga
-
Málaga, Málaga, España, 29016
- Reclutamiento
- Vithas Hospital Parque San Antonio
-
-
Seville
-
Castilleja de la Cuesta, Seville, España, 41950
- Reclutamiento
- Hospital Vithas Nisa Sevilla
-
-
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85032
- Reclutamiento
- Arizona Neuroscience Research, LLC
-
Scottsdale, Arizona, Estados Unidos, 85253
- Reclutamiento
- Perseverance Research Center, LLC (PRC)
-
-
California
-
Fullerton, California, Estados Unidos, 92835
- Reclutamiento
- Fullerton Neurology and Headache Center
-
Torrance, California, Estados Unidos, 90502-2006
- Reclutamiento
- Harbor-UCLA Medical Center - The Lundquist Institute (Los Angeles Biomedical Research Institute (LA BioMed))
-
West Hollywood, California, Estados Unidos, 90048
- Reclutamiento
- Regina Berkovich MD, PhD Inc
-
-
Florida
-
Boca Raton, Florida, Estados Unidos, 33487
- Reclutamiento
- SFM Clinical Research, LLC
-
Bradenton, Florida, Estados Unidos, 34209
- Reclutamiento
- Nova Clinical Research, LLC
-
Clearwater, Florida, Estados Unidos, 33761
- Reclutamiento
- MS and Neuromuscular Center of Excellence
-
Maitland, Florida, Estados Unidos, 32751
- Reclutamiento
- Neurology Associates
-
Naples, Florida, Estados Unidos, 34105
- Reclutamiento
- Aqualane Clinical Research
-
Tampa, Florida, Estados Unidos, 33612
- Reclutamiento
- University of South Florida Department of Neurology - MS Division
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46256
- Reclutamiento
- Josephson Wallack Munshower Neurology, Pc Suite 225
-
-
Kansas
-
Kansas City, Kansas, Estados Unidos, 66160
- Reclutamiento
- University of Kansas Medical Center
-
Roeland Park, Kansas, Estados Unidos, 66205
- Reclutamiento
- KC Research Center, PA Neurology Research Dept
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02131
- Retirado
- Boston Clinical Trials
-
Worcester, Massachusetts, Estados Unidos, 01655
- Reclutamiento
- University of Massachusetts Memorial Medical Center
-
-
Michigan
-
Rochester Hills, Michigan, Estados Unidos, 48307
- Reclutamiento
- Profound Research LLC at Oakland Neurology Center
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110
- Reclutamiento
- Washington University School of Medicine
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos, 87131
- Reclutamiento
- University Of New Mexico School Of Medicine
-
-
New York
-
New York, New York, Estados Unidos, 10029
- Reclutamiento
- Mount Sinai Medical Center
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43235
- Reclutamiento
- The Boster Center for Multiple Sclerosis
-
Columbus, Ohio, Estados Unidos, 43221
- Reclutamiento
- The Ohio State University Wexner Medical Center (OSUWMC)
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- Reclutamiento
- OMRF Multiple Sclerosis Center of Excellence
-
-
South Carolina
-
Greenville, South Carolina, Estados Unidos, 29605
- Reclutamiento
- Premier Neurology
-
-
Tennessee
-
Cordova, Tennessee, Estados Unidos, 38018
- Reclutamiento
- Neurology Clinic, P.C.
-
-
Texas
-
San Antonio, Texas, Estados Unidos, 78258
- Reclutamiento
- Lone Star Neurology
-
Sherman, Texas, Estados Unidos, 75092
- Reclutamiento
- Texas Institute for Neurological Disorders - Sherman
-
-
-
-
Harju
-
Tallinn, Harju, Estonia, 10617
- Reclutamiento
- Astra clinic (Clinic4U)
-
-
-
-
Brest
-
Pordic, Brest, Francia, 29609
- Reclutamiento
- CHU Brest Hospital Cavale
-
-
Gard
-
Nîmes, Gard, Francia, 30029
- Reclutamiento
- Centre Hospitalier Universitaire de Nimes (CHU) - Hopital Universitaire Caremeau
-
-
Yveline
-
Poissy, Yveline, Francia, 78300
- Reclutamiento
- Centre Hospitalier Intercommunal (Chi) Poissy-Saint-Germain-En-Laye - Site De Poissy
-
-
-
-
-
Tbilisi, Georgia, 0114
- Reclutamiento
- LTD Pineo Medical Ecosystem
-
Tbilisi, Georgia, 0186
- Reclutamiento
- Raymann, LLC
-
Tbilisi, Georgia, 0159
- Reclutamiento
- NNLE Jo Ann University Hospital
-
Tbilisi, Georgia, 0186
- Reclutamiento
- Caucasus Medical Center Ltd
-
-
K'alak'i T'bilisi
-
Tbilisi, K'alak'i T'bilisi, Georgia, 0114
- Reclutamiento
- JSC Curatio
-
-
Saburtalo
-
Tbilisi, Saburtalo, Georgia, 0160
- Reclutamiento
- MD Georgia Staff Physician MediClub Georgia
-
-
-
-
Athens
-
Cholargós, Athens, Grecia, 15562
- Reclutamiento
- Metropolitan General Hospital
-
-
Attica
-
Athens, Attica, Grecia, 11526
- Reclutamiento
- Errikos Dunant Hospital
-
-
-
-
-
Budapest, Hungría, 1145
- Reclutamiento
- National Institute of Clinical Neurosciences
-
Tatabánya, Hungría, 2800
- Reclutamiento
- Komarom-Esztergom Varmegyei Szent Borbala Korhaz
-
-
Komarom-Esztergom Vamegye
-
Esztergom, Komarom-Esztergom Vamegye, Hungría, 2500
- Reclutamiento
- Valeomed Kft.
-
-
-
-
Chieti
-
Chieti, Chieti, Italia, 66100
- Reclutamiento
- University G. D'Annunzio of Chieti-Pescara
-
-
Isernia/Molise
-
Pozzilli, Isernia/Molise, Italia, 86077
- Reclutamiento
- IRCCS Istituto Neurologico Mediterraneo Neuromed
-
-
-
-
Kauno
-
Kaunas, Kauno, Lituania, 50161
- Reclutamiento
- Hospital of Lithuanian University of Health Sciences
-
-
-
-
-
Lublin, Polonia, 20-064
- Reclutamiento
- Galen Clinic
-
Plewiska, Polonia, 62-064
- Reclutamiento
- Neurologiczny Niepubliczny ZOZ Centrum Leczenia SM Osrodek Badan Klinicznych im. dr n. med. Hanki Hertmanowskiej
-
Poznan, Polonia, 15-540
- Reclutamiento
- Prywatna Lecznica Certus Sp. z o.o.
-
Szczecin, Polonia, 70-111
- Reclutamiento
- EUROMEDIS Osrodek Badan Klinicznych
-
Żory, Polonia, 44-240
- Reclutamiento
- Centrum Medyczne ProNeuro Żory
-
-
Kuyavian-Pomeranian Voivodeship
-
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Polonia, 85-605
- Reclutamiento
- Centrum Medyczne INTERCOR Sp. z o.o.
-
-
Lublin Voivodeship
-
Lublin, Lublin Voivodeship, Polonia, 20-601
- Reclutamiento
- Malva Trials
-
Lublin, Lublin Voivodeship, Polonia, 20-064
- Reclutamiento
- Instytut Naukowo-Badawczy w Lublinie Sp. z o.o.
-
Lublin, Lublin Voivodeship, Polonia, 20-064
- Reclutamiento
- NZOZ Neuromed M. i M. Nastaj Sp.P
-
-
Lubusz Voivodeship
-
Nowa Sól, Lubusz Voivodeship, Polonia, 67-100
- Reclutamiento
- Twoja Przychodnia Centrum Medyczne Nowa Sól
-
-
Mazovian
-
Warsaw, Mazovian, Polonia, 02-172
- Reclutamiento
- MTZ Clinical Researcz Powered by pratia
-
-
Rzeszów
-
Rzeszów, Rzeszów, Polonia, 35-323
- Reclutamiento
- Nmedis sp. z o.o.
-
-
Silesian Voivodeship
-
Katowice, Silesian Voivodeship, Polonia, 40-081
- Reclutamiento
- Centrum Medyczne Pratia Katowice
-
Katowice, Silesian Voivodeship, Polonia, 40-571
- Reclutamiento
- MA-LEK Clinical Sp. z o.o.
-
Katowice, Silesian Voivodeship, Polonia, 40-584
- Reclutamiento
- NZOZ Novo Med
-
-
Upper Silesia
-
Katowice, Upper Silesia, Polonia, 40-686
- Reclutamiento
- Neuro Medic Clinic
-
-
Wielkopolska
-
Poznan, Wielkopolska, Polonia, 61-853
- Reclutamiento
- Nzoz Neuro-Kard Ilkowski I Partnerzy Spolka Partnerska Lekarzy
-
Poznan, Wielkopolska, Polonia, 60-324
- Reclutamiento
- Twoja Przychodnia PCM
-
-
Łódź Voivodeship
-
Lodz, Łódź Voivodeship, Polonia, 91-743
- Reclutamiento
- PRO SALUS Sp. z o.o. sp.k.
-
Lodz, Łódź Voivodeship, Polonia, 90-324
- Reclutamiento
- Centrum Neurologii Krzysztof Selmaj
-
-
-
-
-
Guaynabo, Puerto Rico, 00969
- Reclutamiento
- Caribbean Center for Clinical Research
-
-
-
-
Constanța County
-
Constanța, Constanța County, Rumania, 900123
- Reclutamiento
- Spital Clinic CF Constanta
-
-
Suceava
-
Radauti, Suceava, Rumania, 725400
- Reclutamiento
- Spitalul Municipal Sf. Doctori Cosma si Damian Radauti
-
-
-
-
-
Kragujevac, Serbia, 34000
- Reclutamiento
- University Clinical Centre of Kragujevac
-
Niš, Serbia, 18000
- Reclutamiento
- Clinic of Neurology - Clinical Center Nis
-
-
Belgrade
-
Belgrade, Belgrade, Serbia, 11000
- Reclutamiento
- University Clinical Centre of Serbia
-
-
-
-
-
Ivano-Frankivsk, Ucrania, 76943
- Reclutamiento
- Neuro Global
-
Lviv, Ucrania, 79010
- Reclutamiento
- Lviv National Medical University named after Danylo Galytskiy
-
Vinnytsia, Ucrania, 21009
- Reclutamiento
- Medical Clinical Investigational Center of Medical Center LLC Health Clinic
-
-
Chernivtsi Oblast
-
Chernivtsi, Chernivtsi Oblast, Ucrania, 58023
- Reclutamiento
- Regional Municipal Non-commercial Enterprise Chernivtsi Emergency Medical Hospital
-
-
Ivano-Frankivs'k Oblast
-
Ivano-Frankivsk, Ivano-Frankivs'k Oblast, Ucrania, 76018
- Reclutamiento
- CNE City Clinical Hospital #1 of Ivano-Frankivsk council
-
-
Lviv Oblast
-
Lviv, Lviv Oblast, Ucrania, 79000
- Reclutamiento
- Limited Liability Company Medical Center Neuroclinic
-
Lviv, Lviv Oblast, Ucrania, 79029
- Reclutamiento
- Limited Liability Company "Neurofocus"
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- 18 to 60 years of age, inclusive, at the time of signing the informed consent.
- Participant must have a previous diagnosis of RRMS in accordance with 2024 McDonald criteria
- Participant must have a current diagnosis of SPMS in accordance with the clinical course criteria revised in 2013
- Participant must have documented evidence of disability progression independent of clinical relapse observed during the 24 months before screening. A written summary of the clinical evidence of disability progression must be discussed and aligned between the Investigator and the Sponsor's dedicated qualified person(s).
- Absence of clinical relapses for at least 24 months.
Exclusion Criteria:
- The patient has been diagnosed with primary progressive MS (PPMS) according to 2024 McDonald diagnostic criteria
- Immunologic disorder other than MS or any other conditions requiring corticosteroid therapy.
- History or current diagnosis of other neurological disorders that may mimic MS
- History or current diagnosis of progressive multifocal leukoencephalopathy
- Active, clinically significant viral, bacterial, or fungal infection
- History of any other significant active medical condition
- History of suicidal behavior within 6 months prior to Screening
- Any prior history of malignancy
- Patients on anticoagulation, or antiplatelet therapy
- Patients took strong/moderate CYP3A inhibitors or strong/moderate CYP3A inducers within 14 days
- Clinically significant laboratory abnormalities at Screening.
- Vaccination with live or live-attenuated virus vaccine within 1 month prior to Screening
- History of alcohol abuse or alcohol use disorder or other drug abuse within 12 months prior to screening.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Orelabrutinib Group
Orelabrutinib PO daily |
Orelabrutinib orally |
|
Comparador de placebos: Placebo Group
Placebo PO daily |
Placebo orally |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Time to onset of confirmed disability progression (CDP) events, confirmed over at least 24 weeks
Periodo de tiempo: Up to approximately 120 weeks
|
Expanded disability status scale (EDSS) score increase ≥ 1.0 point from baseline when the baseline score is ≤ 5.0, or ≥ 0.5 points from baseline when the baseline score is > 5.0 |
Up to approximately 120 weeks
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
12 Week CDP
Periodo de tiempo: Up to approximately 120 weeks
|
Time to onset of CDP events on EDSS, confirmed over at least 12 weeks |
Up to approximately 120 weeks
|
|
T2 lesions on MRI
Periodo de tiempo: Up to approximately 120 weeks
|
The total number of new or enlarging T2 lesions on MRI scans of the brain |
Up to approximately 120 weeks
|
|
24-week CDP-9-hole Peg Test
Periodo de tiempo: Up to approximately 120 weeks
|
Time to onset of CDP events on 9-hole Peg Test (9HPT), defined as ≥ 20% increase on 9HPT from baseline, confirmed over at least 24 weeks |
Up to approximately 120 weeks
|
|
24-week CDP-T25FWT
Periodo de tiempo: Up to approximately 120 weeks
|
Time to onset of CDP events on Timed 25-Foot Walk Test (T25FWT), defined as ≥ 20% increase on T25FWT from baseline, confirmed over at least 24 weeks |
Up to approximately 120 weeks
|
|
24-week CDI
Periodo de tiempo: Up to approximately 120 weeks
|
Time to onset of confirmed disability improvement (CDI) events on EDSS, defined as ≥ 1.0-point decrease on the EDSS score from baseline when the baseline score is ≤ 5.0, or ≥ 0.5 points from baseline when the baseline score is > 5.0, confirmed over at least 24 weeks |
Up to approximately 120 weeks
|
|
24-week CDI-9HPT
Periodo de tiempo: Up to approximately 120 weeks
|
Time to onset of CDI events on 9HPT, defined as ≥ 20% decrease on the 9HPT score from baseline, confirmed over at least 24 weeks |
Up to approximately 120 weeks
|
|
24-week CDI-T25FWT
Periodo de tiempo: Up to approximately 120 weeks
|
Time to onset of CDI events on T25FWT, defined as ≥ 20% decrease on the T25FWT score from baseline, confirmed over at least 24 weeks |
Up to approximately 120 weeks
|
|
Symbol Digit Modalities Test
Periodo de tiempo: Up to approximately 120 weeks
|
The change in cognitive function as assessed by Symbol Digit Modalities Test (SDMT) from baseline to each scheduled visit |
Up to approximately 120 weeks
|
|
Annualized relapse rate
Periodo de tiempo: Up to approximately 120 weeks
|
Annualized relapse rate (ARR) during the study period assessed by protocol-defined adjudicated relapses |
Up to approximately 120 weeks
|
|
To evaluate the safety and tolerability of orelabrutinib
Periodo de tiempo: Up to approximately 120 weeks
|
Safety as assessed by the nature, severity, and incidence of adverse events (AEs) (graded according to National Cancer Institute-Common Terminology Criteria for AEs, NCI-CTCAE version 5.0); |
Up to approximately 120 weeks
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Nervioso
- Procesos Patológicos
- Enfermedad crónica
- Atributos de la enfermedad
- Enfermedades autoinmunes
- Enfermedades del sistema inmunológico
- Enfermedades Autoinmunes Desmielinizantes, SNC
- Enfermedades Autoinmunes del Sistema Nervioso
- Enfermedades desmielinizantes
- Condiciones Patológicas, Signos y Síntomas
- Esclerosis múltiple
- Esclerosis Múltiple Crónica Progresiva
- orelabrutinib
Otros números de identificación del estudio
Otros números de identificación del estudio
- ZB020-03-002
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .